Dan Zhao

Assistant professor

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (16)

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Collaborators (8)

Eugene J. Koay

UNITED STATES

View details

Matthew H. G. Katz

UNITED STATES

View details

Mehnaz Shafi

Professor of Medicine

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Deyali Chatterjee

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Anirban Maitra

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Deric L. Wheeler

UNITED STATES

View details

Yinghong Wang

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Leonidas Arvanitis

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Dan Zhao

Research Interests

Explore related searches

Contact this professor

Articles (16)

The Effect of Immune Checkpoint Inhibitor Therapy on Pre-Existing Gastroparesis and New Onset of Symptoms of Delayed Gastric Emptying

Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcome

Impact of <i>KRAS</i> mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma

Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles

Comparative Analyses of the Clinicopathologic Features of Short-Term and Long-Term Survivors of Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreatoduodenectomy.

Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy.

Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy.

Characteristics, treatment, and outcome of patients with bowel perforation after immune checkpoint inhibitor exposure.

Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles

Comparative Analyses of the Clinicopathologic Features of Short-Term and Long-Term Survivors of Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreatoduodenectomy

Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy

Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

Mesalamine and cholestyramine for immune checkpoint inhibitor-mediated diarrhea and colitis.

Immune checkpoint inhibitor-related gastrointestinal toxicity in patients with malignancy involving the luminal gastrointestinal tract and its impact on cancer outcomes.

Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors.

Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors.

Collaborators (8)

Eugene J. Koay

Matthew H. G. Katz

Mehnaz Shafi

Deyali Chatterjee

Anirban Maitra

Deric L. Wheeler

Yinghong Wang

Leonidas Arvanitis

Make your next move.